We help our customers to deal with challenging recombinant proteins related projects. To see some solved ones, please provide us with your name and email address. We will be happy to send you selected case studies presentation showcasing our competences. Maybe issues you are facing now, are already described there...
Innovative drug for the immunotherapy of cancer
Title: The development of a drug based on a bispecific antibody for the immunotherapy of cancer
Project no. POIR.01.01.01-00-0947/17
The aim of this project is to develop a bispecific recombinant antibody – a drug candidate for the immunetherapy of patients suffering from colorectal cancer. To deliver this antibody, we will use our proprietary platforms for in vitro antibody selection – PureSelect and PureSelect2. A developed bispecific will target inhibitory route in T cells and will be further tested in preclinical and clinical trials (I phase).
Our strategy here is modulation of immunological check points. As a result, PureBody-1 will endure, which allows for an active fighting off cancer cells.